We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Company would have been better off following Roche’s route to market for anti-obesity treatment
US drugmaker is trying to chart its future without blockbuster Covid-19 products
Case studies in best practice among general counsel and company legal teams in North America
Decision is setback for US drugmaker looking to increase sales after pandemic
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
Companies have yet to provide investors with convincing post-pandemic strategies
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Massachusetts police chief and former pharmaceutical executive also among those indicted by federal prosecutors
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal
US drugmaker adjusts strategy of pursuing deals to replenish drug pipeline
European health officials have advocated portfolio diversity to help fight different variants
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Acquisition price tag will leave investors feeling queasy
US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity
Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs
US drugmaker expects revenues of between $67bn and $71bn this year, down from a record
Officials row with Pfizer over price as villages struggle to obtain antiviral medication
Demand for antiviral treatment has rocketed after jump in infections following Beijing policy U-turn
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
Pfizer’s antiviral ‘more coveted than Moutai’ as authorities restrict imports despite virus wave
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
UK Edition
